Studies on the Genotoxic and Mutagenic Potentials of Mefloquine. by Akerele, JO & Obaseiki-Ebor, EE
JO Akerele & EE Obaseiki-Ebor 
Trop J Pharm Res, December 2002; 1 (2) 91 
Tropical Journal of Pharmaceutical Research, December 2002; 1 (2): 91-98 
 
© Pharmacotherapy Group,  
Faculty of Pharmacy, University of Benin,  
Benin City, Nigeria.  
All rights reserved. 
 










   
  
Studies on the Genotoxic and Mutagenic 
Potentials of Mefloquine 
 
John O Akerele † and Emmanuel E Obaseiki-Ebor 




Purpose: The detection of mefloquine mutagenicity has not been achieved by the use of 
Salmonella typhimurium his TA1535, TA1537 as tester strains.  With the introduction of 
improved and more sensitive strains, it is of interest to evaluate the current mutagenic and 
genotoxic status of the drug.  This study presents data on the in-vitro mutagenic and 
genotoxic potentials of mefloquine hydrochloride clinically used as an antimalarial agent. 
Method: The mutagenicity potentials was investigated in the Escherichia coli WP2 trp and 
WP2 uvrA trp tester strains containing the plasmids, pEB017 and pKM101, and the 
Salmonella typhimurium TA97 containing pKM101. The genotoxicity potential was determined 
using the microscreen phage-induction assay. 
Results: The presence of plasmids pEBO17 and pKM101 enhanced the detection of 
mutagenicity of mefloquine. Microsomal-activated mefloquine unequivocally elicited base-pair 
substitution mutagenicity. The genotoxicity test indicated that mefloquine was generally not 
genotoxic but was of the same potential mutagenicity as chloroquine phosphate. 
Conclusion: Melfloquine hydrochloride exhibits base pair substitution mutagenesis, but not 
potentially genotoxic, even though it showed concentration dependent cytotoxicity.  Its use as 
a last line antimalarial agent should still be encouraged. 
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Introduction 
 
The use of Salmonella typhimurium his 
TA1535, TA1537 etc. strains1, 2 introduced a 
novel epoch in the rapid detection of 
mutagenic or carcinogenic chemical 
compounds.  These strains, however, would 
not detect mefloquine - a quinoline-methanol 
antimalarial agent developed against 
chloroquine resistant Plasmodium sp) to be 
mutagenic.  With the introduction of the 
improved and more sensitive Salmonella 
typhimurium his strains such as TA97, TA98, 
TA100, etc3, 4 and other bacterial strains and 
bacteriophages, using more sensitive assay 
procedures to detect environmental 
genotoxic agents, it became necessary to 
reassess the mutagenicity and genotoxicity 
status of mefloquine.  Mefloquine is one of 
the last line therapeutic drugs recently 
developed against the increasingly prevalent 
chloroquine – resistant Plasmodium 
falciparium parasite, a causative agent of 
chloroquine – resistant malarial fever.  
 
The improved Salmonella typhimurium his 
TA97 strain is known to be very sensitive for 
the detection of frameshift mutagens4. 
Escherichia coli trp WP2 tester strains also 
detect base-pair substitution mutagenesis5, 6.  
Salmonella typhimurium his TA97 was 
proposed as a replacement for TA15373, 4 
and it also contained the plasmid pKM101 
which had been reported to enhance error-
prone DNA repair and mutagenesis1, 7.  A 
novel plasmid pEB0178 has also been 
reported to enhance bacterial mutagenesis9 
which was incorporated into the E. coli trp 
WP2 tester strains as WP2 trp (pEB017).  
The suitably modified protocol of the highly 
sensitive microscreen prophage induction 
assay earlier described10, 11 was adapted for 
determining the genotoxicity potential of 
mefloquine. Microscreen phage induction 
assays detects potential genotoxins, 
mutagens and carcinogen which are as 
sensitive as the mutagenicity test of Ames et 
al.2. Activation of the compound through their 
prophage inducing activity in bacgteria has 
correlated well with their carcinogenic and 
genotoxic activities12. It measures the 
formation of prophage from a complex 
molecular events through the induction of the 
‘SOS’ molecular response - a cellular 
reaction to DNA damage.  The present study 
is designed to ascertain the mutagenicity 
and genotoxicity status of mefloquine using 
Salmonella typhimurium his TA97 and E. coli 






The Salmonella typhimurium his TA97 
strains contains R-plasmid pKM1013, 4 and 
mediates frameshift mutagenesis on 
reversion from His− to His+ by a putative 
mutagen.  The Escherichia coli WP2 strains 
were WP2 trp uvrA
5, 6, WP2 (pKM101) trp
13 
and WP2 (pEB017) trp
8.  These E. coli 
strains respond to base-pair substitution 
mutagenesis by reverting from Trp− 
auxotrophs to Trp+ prototrophs. 
Bacteriophage – lambda lysogen E. coli 
WP2s (lambda) F−. trp and the indicator 
strains E. coli TH-008 (streptomycin 
resistant) were provided by Dr. Toby E. 
Rossman of the Institute of Environmental 
Medicine New York. Purified single colony 
isolates of all the tester strains were 
subcultured on nutrient agar slants and 




Nutrient broth No. 2 (Oxoid); nutrient agar 
(Oxoid); agar No. 1 (Oxoid); Davis and 
Mingioli (DM) 195014 salts solution; Vogel-
Bonner minimal medium supplemented with 
0.2% w• v glucose; Salmonella mutagenicity 
test plates were prepared as directed4.  E. 
coli trp mutagenicity test plates were 
prepared with and without the inclusion of 20 
mg/ml tryptophan.  Tryptone medium (10 g 
of Bactone tryptone, 6 g of NaCl and 12 g of 
Bacto agar per litre of distilled water).  
Streptomycin (100 mg/ml) was added to the 
tryptone medium to select against the 
lysogen. 
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Drugs and biochemical 
 
A stock solution (1 mg/ml) of mefloquine 
hydrochloride (obtained from Walter Reed 
Army Institute of Research, Washington, 
D.C., USA) was prepared and sterilised by 
filtration with bacteria proof membrane filters 
(Millipore, USA) and stored in an amber 
coloured bottle.  Chloroquine phosphate, 
nalidixic acid (sodium salt), 2-nitrofluorene 
(used as positive controls to induce 
prophage) and reduced nicotinamide 
adenine dinucleolide phosphate (NADPH) 





Albino (Sprague-Dawley) rats weighing 130-
200 g were injected peritoneally with pheno-
barbitone sodium (50 mg/kg) for seven 
consecutive days before they were killed.  
The livers of the rats were aseptically 
removed and pooled in a beaker containing 
TrisHCl (pH 7.5) at approximately 3 ml/g wet 
liver as earlier described15. 
 
Preparation of liver homogenate fraction (S-
9) 
 
The procedure of Ames et al.2 was modified 
where necessary.  The liver lobes were 
minced with sterile scissors and manually 
homogenized in a mortar and pestle that had 
been oven-sterilised and cooled to 4° C.  
The homogenate was centrifuged at 9000 xg 
for 20 min in an high speed 18 centrifuge 
(MSE, Sanyo, UK) at 4° C.  The supernatant 
was carefully decanted into a sterile 
universal bottle and kept on ice.  The liver 
extract (S-9) was immediately used for the 
mutagenicity tests after determining its 
protein concentration. The protein concen-
tration was estimated using the method of 
Lowry et al.16 with bovine serum albumin as 
standard. 
 
Determination of minimum inhibitory 
concentration (MIC) of mefloquine 
 
The MIC of mefloquine against the test 
bacterial strains was determined by the agar 
dilution protocol as previously described13.   
 
Mutagenicity testing  
 
Mutatenicity testing was carried out by the 
plate incorporation method with and without 
activation using the method of Brusick et 
al.17 was suitably modified as previously 
validated15.  Sub-inhibitory concentrations of 
mefloquine (2.5 and 5 µg/ml) were added to 
tubes containing 2.5 ml of molten overlay 
agar (0.7% w/v agar-agar) held at 45° C.  An 
aliquot of 0.1 ml of undiluted, washed test 
culture were added to the tubes. The 
contents of the tubes were gently mixed and 
immediately poured onto the top of the 
prepared mutagenicity test agar plate and 
allowed to solidify.  Positive control plates 
(containing 20 µg/ml tryptophan or histidine 
and no test agent) and negative control 
plates were also prepared.  All plates were 
incubated at 37° C for 48 hr and the mean 
number of colonies growing per plate in 
triplicate experiments were recorded. 
 
Activation was achieved in the plate 
incorporation method with NADPH and the 
enzyme preparation (S-9 mix). In this case, a 
sub-inhibitory concentration of mefloquine 
(0.1 ml of the undiluted test culture), 0.1 ml 
of NADPH 10mg/ml stock solutions, and 0.5 
ml of the S-9 extract (3.13 ml/ml protein) at 
4° C were mixed in sterile universal bottles 
and incubated at room temperature for 15 
min.  This mixture was added to 2.5 ml 
molten overlay agar (0.7%) held at 45° C 
and immediately poured on the top of the 
prepared mutagenicity test plates and the 
respective control plates allowed to solidify 
followed by the subsequent incubation at 37° 
C for 48 hr. 
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Tubes fluctuation test  
 
The method of Green et al.18 was suitably 
modified as earlier validated15.  A fresh 
overnight washed test culture in 10 ml Davis 
& Mingioli liquid medium appropriately 
supplemented with either 20 µg/ml of 
histidine or tryptophan and 200 µg/ml of 
glucose was grown to log phase, harvested 
and washed free of the histidine or 
tryptophan supplement. The resuspended 
culture, 0.4ml (1 × 109 cfu/ml) in 10ml sterile 
distilled water was inoculated into 400 ml 
Davis & Mingioli basal salts containing 
glucose (200 µg/ml), biotin (5 µg/ml) and 
bromocresol purple indicator 12 µg/ml.  The 
contents were thoroughly mixed and 
aseptically divided into 4 portions of 200ml 
as follows: 100 ml aliquot containing test 
concentrations of mefloquine (in duplicate); 
100 ml aliquot containing additional 
concentrations of histidine or tryptophan (20 
µg/ml); 100 ml aliquot containing no 
histidine, tryptophan or mefloquine. The 
contents of each flask were aseptically 
dispensed in 2 ml aliquot to 50 small sterile 
test tubes and incubated at 37° C.  As from 
72 hr of incubation, the tubes containing His+ 
or Trp+ revertants were turbid  changing their 
colouration from purple to yellow and were 
recorded.  Each duplicate test concentration 
of mefloquine was determined on at least 
two occasions. 
 
For tubes fluctuation test with S-9 activation, 
the broth was supplemented minimal salts 
aliquot (above) contained, in addition to the 
test culture, 0.25 ml of the S-9 extract (3.13 
mg/ml), protein (0.5 ml of 10mg/l NADPH) 
and the appropriate concentration of 
mefloquine.   
 
Prophage Induction Assay 
 
The microscreen prophage induction assay 
was performed as described by DeMarini et 
al.11.  Sterile plastic 96-well microlitre plates 
(Corning, New York, USA) were used for the 
microsuspension assay.  Briefly, the first well 
in a dilution series of the 96 well microlitre 
plates had 250 µl of supplemented Vogel-
Bonner minimal salts containing 0.2% 
glucose and 20 µg/ml of tryptophan and 50 
µl of either the mefloquine (100 µg/ml) or the 
control i.e., nalidixic acid and/or 2-
nitrofluorene.  The remaining wells had 150 
µl of the medium with subsequent two-fold 
serial dilution of each well content down the 
column of each plate.  Each well was 
inoculated with 75 µl (about 2 × 105 cells) of 
a resuspended log-phase culture of WP2s
11.  
In case of microsomal activation of the 
mefloquine, 25 µl of the prepared S-9 mix 
100 µl of NADPH (10 mg/ml) were added to 
each well.  Contents of each microlitre plate 
were mixed using a minimixer (Fisson plc, 
Loughborougb, UK), the lid was placed 
tightly on the plate, and the plates were 
incubated overnight at 30° C. 
 
Assay for plaque formation 
 
After incubation, the wells were scored for 
turbidity.  Turbid wells indicated cell growth 
and clear wells indicated genotoxicity and/or 
inhibition of cell growth.  The concentration 
of the lambda phage was determined by 
sampling the first three turbid wells. 
Whenever there was a clear well, samples 
were obtained from the first three wells 
adjacent to the last clear well.  A sample (50 
µl) from a well was diluted in 2.5 ml of the 
supplemented minimal medium and 100 µl of 
the dilution was added to about 2.5 ml of top 
agar (0.6% Bacto agar and 10 mM MgSO4) 
along with 200 µl of log-phase indicator cells 
(TH-008), which had been grown in Oxoid 
No. 2 nutrient broth.  The content of each 
tube was poured onto bottom agar made of 
tryptone medium. The plates were incubated 
overnight at 37° C and plaques were 
counted.  The number of plaques from a 
dilution series of the microlitre plate that did 
not contain any test compound (control) was 
also determined. 
 
Analysis of data 
 
Scoring by Houk and DeMarini10, 11 and 
DeMarini et al.19 were adopted.  Induced 
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plaque forming unit per plate (i.e., PFU/plate 
that reached the upper limit of the 99% 
confidence interval) represents an 
approximate three-fold increase over the 
background (tubes without any test 
compound or control).  A dose-related 
increase of induced PFU/plate that reached 
or exceeded a three-fold increase in 
PFU/plate was considered a positive 
response.  If a compound’s response 
reached or exceeded the fold increase at 





The plate incorporation tests showed that the 
repair-deficient strain, WP2 uvrA responded 
positively to activated mefloquine when 
compared with the negative response with 
WP2 trp, which are DNA-repair proficient. 
Strains TA97, WP2 trp (pEB017), WP2 
(pKM101) – all bearing mutator R-plasmids – 
responded positively to activated mefloquine 
mutagenicity (Table 1). It would also be seen 
from the tube fluctuation tests that 
microsomally activated mefloquine elicited 
base-pair substitution mutation with the 
tester strains bearing mutator R-plasmids 
(Table 2). The activated mefloquine elicited 
prophage induction to the same level as 
chloroquine phosphate (Table 3). 
 
Mefloquine hydrochloride was dose 
dependently bactericidal against all the test 
bacterial strains with a minimum inhibitory 
concentration (MIC) of 20 µg/ml except 
against the test host strains that had R-
plasmids and the MIC was 40 µg/ml.  The 
fluctuation mutagenicity tests were generally 
more sensitive than the plate incorporation 
method probably because of the greater 
diffusion of mefloquine molecules in liquid 
medium than in solid medium (Tables 1 and 
2). Mutagenicity tests indicated that 
activation of mefloquine hydrochloride 
produced mutagenic products that mediated 
base-pair substitution mutation in the E. coli 
WP2 trp (pEB017) tester strains. The S. 
typhimurium his TA97 strains also mediated 
a weak frameshift mutation but mefloquine 
mutagenicity potential was most remarkable 




The effect of plasmid pEB017 in 
demonstrating enhanced induction of 
reversion of E. coli WP2 trp from Trp
– to Trp+ 
compared to the enhanced reversion 
induction effect of the well known plasmid 
pKM101 in the isogenic E. coli WP2 trp 
indicated the superiority of pEB017 to 
pKM101 in E. coli host strains.  It was also 
observed that there was a relative decreased 
number of revertants by higher concentration 
of mefloquine, thus indicating the toxicity of 
mefloquine hydrochloride (Table 2) hence 
induced revertants were obtained at 2.5 
µg/ml of mefloquine hydrochloride but not at 
5.0 µg/ml.  It could therefore be suggested 
that compounds that are bactericidal and 
mutagenic have an optimum concentration 
that induced mutations, beyond the critical 
level, the bacterial tester strains reversion 
response and cell survival would be 
impaired.  This phenomenon was earlier 
observed in nitrofurantoin and chlorpro-
mazine hydrochloride mutagenicity15, 20. 
 
Our data also showed that the presence of 
R-mutator plasmids (pKM101 and pEB017) 
enhance detection of activated mefloquine 
as a base-pair mutagen. The positive 
response of the repair deficient tester 
strains, WP2 uvrA, without R-plasmids to 
activated mefloquine showed possible 
mediation of DNA damage repair enzymes in 
the observed base-pair mutagenic events. 
Generally, WP2 uvrA strains are sensitive 
determinanats of base-pair substitution 
mutagens3. The observed negative activity in 
WP2 strains could be attributed to non-
penetration or weak penetration of the 
bacterial cells by mefloquine. Possible 
facilitation of entry of the activated 
mefloquine into the bacterial tester strains 
are indicated by the positive response with 
activated mefloquine in the presence of 
mutator plasmids. 
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The genotoxicity test indicated that 
mefloquine hydrochloride was not potentially 
genotoxic but concentration dependent 
cytotoxic. This could be seen in the inhibition 
of bacterial growth in wells at concentrations 
of 5 µg/ml whereas the other wells 
containing serial double dilutions supported 
bacterial growth.  This observation agreed 
with the observed bactericidal action of 5 
µg/ml mefloquine hydrochloride in the plate 
incorporation mutagenicity test.  This study 
therefore corroborates the earlier report of 
Table 1: Revertant colonies in mefloquine reversion tests using the Plates Incorporation Tests 
Methods 
 








E. coli WP2 trp 3 2 500  
E. coli WP2 trp  
(microsomal activation) 2 2 480  
E. coli WP2 uvrA trp 1 3 205  
E. coli WP2 uvrA trp 
(microsomal activation) 2 15 200 P < 0.01 
E. coli WP2 trp (pEB017) 3 4 200  
E. coli WP2 trp (pEB017) 
(microsomal activation) 1 12 220 P < 0.01 
E. coli WP2 trp (pKM101) 2 3 480  
E. coli WP2 trp (pKM101) 
(microsomal activation) 1 11 470 P < 0.01 
S. tryphimurium his TA97 3 5 320  
S. tryphimurium his TA97 
 (microsomal activation) 1 18 430 P < 0.01 
 
 Table 2: Turbid tubes in Fluctuation test with mefloquine 
Organisms Positive control per total tubes 
Negative control 
per total tubes 
50 tubes containing 
mefloquine 5 µg/ml Significance 
E. coli WP2 trp 50 2 2  
E. coli WP2 trp 
 (microsomal activation) 50 2 6 P < 0.01 
E. coli WP2 uvrA trp 50 0 1  
E. coli WP2 uvrA trp 
 (microsomal activation) 50 1 7 P < 0.01 
E. coli WP2 trp (pEB017) 50 0 0  
E. coli WP2 trp (pEB017) 
 (microsomal activation) 50 2 9 P < 0.01 
E. coli WP2 trp (pKM101) 50 3 1  
E. coli WP2 trp (pKM101) 
(microsomal activation) 50 3 12 P < 0.01 
S. tryphimurium his TA97 50 0 0  
S. tryphimurium his TA97 
 (microsomal activation) 50 0 8 P < 0.01 
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Davidson et al.21 that mefloquine weakly 
binds to DNA.  The genotoxicity potentials of 
mefloquine favourably compared with the 
negative control (without the test or positive 
compounds) that contained only the growth 
medium. PFU/plate obtained from the 
mefloquine wells contrasted with the positive 
control wells containing nalidixic acid and 2-
nitrofluorene (Table 3), thus indicating that 
mefloquine hydrochloride was not genotoxic. 
Considering the earlier results of 
Schupbach22 that indicated mefloquine to be 
non-mutagenic in the now obsolete tester 
strains, the results of this study constitute an 
instance where the use of an improved tester 
strain (i.e., containing a novel mutator 
plasmid9) and/or the use of a particular 
species of bacterial tester strain enabled the 
detection of a compound as a mutagen that 
was earlier documented to be non-
mutagenic.  Since mefloquine hydrochloride 
exhibits base-pair substitution mutagenesis 
and is not strictly genotoxic, and remains a 
very effective therapeutic antimalarial agent, 
its use as a last line antimalarial agent 
should still be encouraged. 
 
Table 3: Induction of prophage lambda by 
mefloquine hydrochloride, nalidixic acid and 2-
nitrofluorene 
 






chemical) 1 1 1 
Mefloquine 





2.5 1.5 1.1 
Chloroquine 
phosphate 2.5 1.5 1.0 
Nalidixic acid 5.5 6.4 5.9 
2-nitrofluorene 5.8 8.8 7.5 
Values indicate the ratio of proportion of 
PFU/plate in the control (no chemical) to the test 
compound (mefloquine hydrochloride) and the 
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